Synthesis and anti-HIV evaluation of novel 1,3-disubstituted thieno[3,2-c][1,2,6]thiadiazin-4(3H)-one 2,2-dioxides(TTDDs)

Bioorganic and Medicinal Chemistry

Volumn 16, Issue 1, 2008, Pages 157-163

  Lin, Yongqiang ^a   Liu, Xinyong ^a   Yan, Renzhang ^a   Li, Jin ^a   Pannecouque, Christophe ^b   Witvrouw, Myriam ^b   De Clercq, Erik ^b  

^a SHANDONG UNIVERSITY   (China)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

HIV 1 NNRTIs; Synthesis; Thieno 3,2 c 1,2,6 thiadiazine

Indexed keywords

1 (3 CYANO)BENZYL 3 BENZYL THIENO[3,2 C][1,2,6]THIADIAZIN 4(3H) ONE 2,2 DIOXIDE; 2 BENZYL 4 CYANOMETHYLENE 1,1,3 TRIOXO 2H,4H THIENO[3,4 E][1,2,4]THIADIAZINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEVIRAPINE; QM 96625; RNA DIRECTED DNA POLYMERASE INHIBITOR; THIADIAZINE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

CELL LINE; HETEROCYCLIC OXIDES; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; REVERSE TRANSCRIPTASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; THIADIAZINES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 38049086183     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2007.10.013     Document Type: Article

References (18)

1. AIDS Epidemic Update: December 2006, UNAIDS/WHO, http://www.unaids.org.
2. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., Keeling J., Darby G., Jones Y., Stuart D., and Stammers D. Nature Struct. Biol. 2 (1995) 293-302
3. Ding J., Das K., Tantillo C., Zhang W., Clark A.D.J., Jessen S., Lu X., Hsiou Y., Jacobo-Molina A., Andries K., Pauwels R., Moereels H., Koymans L., Janssen P.A.J., Smith R.H.J., Kroeger Koepke R., Michejda C.J., Hughes S.H., and Arnold E. Structure 3 (1995) 365-379
4. Drake S.M. J. Antimicrob. Chemother. 45 (2000) 417-420
5. De Clercq E. J. Med. Chem. 48 (2005) 1297-1313
6. De Clercq E. Expert Opin. Emerging Drugs 10 (2005) 241-273
7. Arranz E., Diaz J.A., Ingate S.T., Witvrouw M., Pannecouque C., Balzarini J., De Clercq E., and Vega S. J. Med. Chem. 41 (1998) 4109-4117
8. Arranz M.E., Díaz J.A., Ingate S.T., Witvrouw M., Pannecouque C., Balzarini J., De Clercq E., and Vega S. Bioorg. Med. Chem. 7 (1999) 2811-2822
9. Witvrouw M., Arranz M.E., Pannecouque C., Declercq R., Jonckheere H., Schmit J.C., Vandamme A.M., Dia J.A., Ingate S.T., Desmyter J., Esnouf R., Van Meervelt L., Vega S., Balzarini J., and De Clercq E. Antimicrob. Agents Chemother. 42 (1998) 618-623
10. Schafer W., Friebe W.G., Leinert H., Mertens H., Poll T., von der Saal W., Zilch H., Nuber B., and Ziegler M.L. J. Med. Chem. 36 (1993) 726-732
11. Martinez A., Esteban A.I., Castro A., Gil C., Conde S., Andrei G., Snoeck R., Balzarini J., and De Clercq E. Antiviral Chem. Chemother. 11 (2000) 221-230
12. Martinez A., Esteban A.I., Castro A., Gil C., Conde S., Andrei G., Snoeck R., Balzarini J., and De Clercq E. Antiviral Chem. Chemother. 12 (2001) 347-351
13. Martinez A., Gil C., Castro A., Bruno A.M., Perez C., Prieto C., and Otero J. Antiviral Chem. Chemother. 14 (2003) 107-114
14. Cohen E., and Klarberg B. J. Am. Chem. Soc. 84 (1962) 1994-1996
15. Kloek J.A., and Leschinsky K.L. J. Org. Chem. 41 (1976) 4028-4030
16. Barreca M.L., Balzarini J., Chimirri A., De Clercq E., De Luca L., Höltje H.D., Höltje M., Monforte A.M., Monforte P., Pannecouque C., Rao A., and Zappala M. J. Med. Chem. 45 (2002) 5410
17. Barreca M.L., Rao A., De Luca L., Zappala M., Monforte A.-M., Maga G., Pannecouque C., Balzarini J., De Clercq E., Chimirri A., and Monforte P. J. Med. Chem. 48 (2005) 3433-3437
18. Pauwels R., Balzarini J., Baba M., Snoeck R., Schols D., Herdewijn P., Desmyter J., and De Clercq E. J. Virol. Methods 20 (1988) 309-321